Sunshine Biopharma enacts 1-for-20 reverse stock split

Published 12/08/2024, 22:32
Sunshine Biopharma enacts 1-for-20 reverse stock split

Sunshine Biopharma, Inc., a Colorado-based pharmaceutical company, announced a significant change to its capital structure. Effective as of last Wednesday, the company executed a 1-for-20 reverse split of its common stock. The reverse stock split became effective in the market on Thursday, August 8, 2024.

The decision to implement a reverse stock split was made public through a filing with the Securities and Exchange Commission (SEC). This strategic move altered the number of shares in circulation, consolidating every twenty shares of issued and outstanding common stock into one single share. The reverse split was enacted through a certificate of amendment to Sunshine Biopharma's articles of incorporation, which was filed with the Secretary of State of Colorado.

Sunshine Biopharma, trading on The Nasdaq Stock Market LLC under the ticker symbol NASDAQ:SBFM for its common stock and NASDAQ:SBFMW for its common stock purchase warrants, has taken this step as part of its corporate strategy. The company, identified by its central index key (CIK) number 0001402328, has not provided additional details regarding the rationale behind the reverse stock split in the SEC filing.

The company's CEO, Dr. Steve N. Slilaty, signed off on the filing, which was dated today, Monday, August 12, 2024. The report did not disclose any immediate financial implications of the reverse stock split, nor did it include forward-looking statements about the company's performance.

In other recent news, Sunshine Biopharma, a pharmaceutical company based in Florida, has announced the full exercise of all Series A Warrants issued in 2024. This development is part of the company's capital raising efforts, potentially leading to an increased number of outstanding shares. On another front, Sunshine Biopharma's subsidiary, Nora Pharma, has received approval from Health Canada to commercialize its biosimilar drug, NIOPEG®, aimed at reducing infection in non-myeloid cancer patients undergoing chemotherapy.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.